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Abstract Asthma is characterized by inflammation of the airways and long-term treatment with inhaled glucocorti-
costeroids improve clinical control in patients previously treated with inhaled rescue beta-2 agonist.We investigated
whether the dose of inhaled glucocorticosteroidwas related to outcome comparedwith oral theophylline.Budesonide
800 mgbd, budesonide 200 mgbd, or theophylline (Theo-Durs 300mgbdwasgivendouble-blind, double-dummy, and
randomized, in a parallelgroup design for 9months; whentherapywas stoppedpatientswere followed for an additional
3 months.Forced expiratory volume in1sec (FEV1), bronchial reactivity, and asthma symptom scoreswere assessed be-
fore entering the study and after1,2,3,5,7, and 9 months of treatment andmonthly after treatment was stopped.Eighty-
five patients (38 females and 47 males) were enrolled in the study during 11/2 year.Withdrawal from the study due to
exacerbations during the treatment period was significantly increased (Po0?01) in the theophylline group. After treat-
mentwas stoppedmore patientswithdrewinthe budesonide group.Inthe budesonide 800 mgbdgroup,FEV1improved
significantly after1month’s treatment (Po0?01) andpersisted throughoutthe studyperiod.In the budesonide 200 mg bd
group,FEV1improved slightly and reached significance (P=0?05) after 5 months of treatment. In the theophylline group,
FEV1 was unchanged during the 9 months of treatment. In both budesonide groups, FEV1 deteriorated significantly
(Po0?01and Po0?02, respectively) after termination of studymedication and reached pretreatment values during the
firstmonth.Inthebudesonide 800 mgbdgroup, theconcentrationof histaminecausinga 20% fallin FEV1 (PC20)increased
significantly (Po0?01) after 1month’s treatment and increased further after 9 months (Po0?0001), equivalent to two
doublingdilutions.In the budesonide 200 mg bd, group PC20 histamine significantly increased (Po0?005) after 2months
of treatment and remained constant; theophylline was unchanged. After treatment with budesonide 800 mg bd and
200 mg bd were stopped, PC20 decreased significantly (Po0?002 and P=0?05, respectively) within the first month.
PC20 remainedunchanged after theophyllinewas stopped.Afterbudesonide 800 mgbdand 200 mgbdtreatment, symp-
tom severitydecreased in a dose-related andhighly significantmanner (Po0?00001and Po0?0001, respectively).With
theophylline, asthma symptoms decreased slightly after1and 2 months treatment (Po0?01and Po0?02, respectively)
and when treatment was stopped no increase in asthma symptoms was evident.Oral theophylline slightly reduced air-
ways symptomsandhadnoinfluenceon FEV1and PC20 histamine.Maintenancetreatmentwithinhaledbudesonidegave a
dose-relatedreductionin airwaysobstruction, bronchialreactivityand asthma symptomseverity.The eff|cacyof inhaled
corticosteroidwas superior to oral theophylline.r2002 Elsevier Science Ltd
doi:10.1053/rmed.2001.1280, available online at http://www.idealibrary.comon
Keywords bronchial asthma; budesonide; inhaled glucocorticosteroid, long-term treatmentINTRODUCTION
Allergic and non-allergic bronchial asthma, is character-
ized by attacks of breathlessness with wheeze and vari-
able airways obstruction.Even inmild asthmatic patientsReceived 28 November 2001and accepted in revised form 29
November 2001
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Aarhus C.,Denmark.Fax: +45 89 49 2110;
E-mail: b.b.larsen@dadlnet.dkin£ammatory changes are present in the bronchial
mucosa (1,2) and the prognosis is related to the levels
of airways obstruction and bronchial responsiveness
(3,4).
Bronchodilators are widely used for asthma treat-
ment, but oral beta-2 agonists do not reduce bronchial
reactivity (5). In recent studies, oral theophylline seems
to reduce bronchial reactivity (6,7). Treatment with in-
haled glucocorticosteroids reduce bronchial hyperreac-
tivity and airways obstruction in short-term studies
(8^11) and long-term studies showed a maintained good
LONG-TERM TREATMENTEFFECTSOFBUDESONIDEORTHEOPHYLLINE 433e⁄cacy for up to 2 years (12^14) . Parts of this study has
been published in (15).This is a presentation of the total
study population including the threemonths follow up.
The present study was designed to investigate
whether prolonged treatment with inhaled budesonide
in£uences lung function, bronchial reactivity and asthma
symptoms and whether a dose or time relationship
existed for the e¡ects.Treatment with oral theophylline
was chosen for comparison. Lung function, bronchial
reactivity and asthma symptoms were followed when
treatments were stopped.
METHODS
Patients
Patients aged above 18 years and without other major
illness were selected from our out-patient clinic. All had
bronchial asthma as de¢ned by the American Thoracic
Society (16).
Patients gave informed consent after verbal and writ-
ten information.The study was approved by the Scienti-
¢c Ethics Committee of Aarhus and TheNational Board
of Health and was performed according to the Declara-
tion of Helsinki. The patients were chosen if they had
asthmawith a symptomduration ofmore than 3months
and were currently treated with inhaled rescue beta-2
agonist only. Patients with conditions or medication
requirements likely to interfere with the purpose of the
study were excluded. Forced expiratory volume in 1sec
(FEV1) had to be equal to ormore than 50% of predicted
normal value (17). All the patients had increased
bronchial reactivity and the concentration of histamine
causing a 20% fall in FEV1 (PC20) was equal to or less than
4mg/ml. None of the patients had been treated with
glucocorticosteroids, cromones or oral bronchodilators
for 4 weeks prior to the study.No patient had bronchial
or respiratory tract infection during the four weeks
preceding the study. Patient characteristics in Table 1
show that the participants hadmoderate asthma.
Study design
The study consisted of three periods:
A baseline period
of1weekdurationwith two clinic visits. At the ¢rst clinic
visit demographic details were obtained and smoking
habits registered. Skin prick test was performed with
nine common allergens (timothy, birch, mugwort, dog,
cat, Dermatophagoides farinae , D. pteronyssinus, Clados-
porium, and Alternaria, Phazets; Pharmacia, Uppsala,
Sweden) and patients were categorized as allergic as
indicated by weal and £are response to one or more
allergens. Lung functionwasmeasured and the broncho-dilator response to 1?25mg inhaled terbutaline was
evaluated. At the second clinic visit bronchial reactivity
to histamine was determined and asthma symptom
score assessed.
A treatment period with a duration of 9 months. Treat-
ment was given with double-dummy technique. Patients
were randomly assigned to budesonide 800mg bd or bu-
desonide 200mg bd inhaled from identical metered-dose
inhalers through a 750ml spacer device (Nebuhalers) or
oral theophylline (Theo-Durs)300mg bd. Patients trea-
ted with theophylline inhaled placebo bd and patients
treated with budesonide had placebo tablets bd. They
were all instructed to rinse their mouth after inhalation
of studymedication and to clean the spacer regularly.Ter-
butaline 0?25mg or salbutamol 0?1mg inhalers were
used as rescuemedication.
During the treatment period assessments at the clinic
took place after 1,2,3,5,7, and 9 months. At each visit
spirometry wasperformed, bronchial reactivity tohista-
mine was determined and asthma symptoms were as-
sessed. Study medication was withheld 12h and inhaled
bronchodilator 8h prior to clinic visits.
No other concomitant asthma medication was al-
lowed. In case of an asthma exacerbationwhich required
treatment with oral corticosteroids patients were with-
drawn from the study.
A follow-up period of a maximum of 3 months duration
where all the study medication was withheld. The pa-
tients continued to use rescue inhaled bronchodilator. In
case of increased pulmonary symptoms the patient was
withdrawn andreceived asthmamedication according to
guidelines (18). At monthly clinical visits lung function
and bronchial reactivity was measured and asthma
symptom score evaluated. Bronchodilator therapy was
stopped 8h prior to the visits.
During thewhole trial patients could visit the clinic at
any time if asthmaworsened.
Lung function
FEV1, forced vital capacity over 6 sec (FVC), and slow
vital capacity (VC) was measured with a dry wedge
spirometer (Vitalograph, Model S, Vitalograph Ltd.,
Buckingham, England) according to standardized guide-
lines (17). At least three reproducible values were
obtained; the highest value was used in the analyses.
Peak expiratory £ow (PEF) was measured with a Mini
Wright peak £owmeter (Clement Clarke Int. Ltd., Eng-
land) with three reproducible measurements and the
highest valuewas used in the analyses.
The bronchodilator response to inhaled beta-2
agonist was determined. FEV1was measured before and
434 RESPIRATORYMEDICINE15min after inhalation of1?25mg terbutaline fromaNeb-
uhalers.
Values were registered as percentage of predicted
normal values according to (17).
Histamine challenge
Bronchial reactivity to histamine was determined in
accordance with a method described by Cockcroft and
co-workers (19).The aerosol was generated by aWright
nebulizer calibrated to give a constant output of 0?13^
0?15ml min1. The mist was inhaled during 2min tidal
breathing, through a mouthpiece with the nose clipped.
FEV1wasmeasuredbefore, 30, and 90 sec after the inha-
lation.FEV1after isotonic salinewasused asbaseline.His-
tamine dihydrochloride was inhaled in doubling
concentrations from 0?03mg ml1 to 32?0mg ml1. The
results were expressed as the PC20 histamine obtained
from the log dose^response curve by linear interpola-
tion.
For statistical analysis a PC20 value of 0?015mg ml
1
was assigned to patients responding to saline and a PC20
value of 33mgml1was assigned if FEV1did not decrease
by 20% after histamine 32mgml1.
Asthma symptomscore
Assessmentof asthma severity was done at clinic visit by
grading various everyday symptoms at rest and after
common exposures: the questions concerned asthma
symptoms by exposure to dust, by exposure to pollu-
tants, by exposure to strong smells, premenstrual symp-
toms, and asthma symptoms when drinking beer orTABLE 1. Patientcharacteristics at inclusion expressed asmean7
Budesonide 800 mg bd
Number Mean (SD)
Number 29
Females/males 14/15
Age, years 29 46?1 (11?2)
Asthma, years 29 6?6 (8?5)
FEV1% predicted 29 70?7 (17?6)
Reversibility FEV1% predicted 25 15?7 (8?7)
PC20 histamine, mg/ml
geometricmean
27 0?33 (0?03-2?87)
Asthma score (0^3) 29 0?9 (0?4)
Smokers/non-smokers 17/12
Allergy 7/4
IgEU/ml 26 70 (104)
Eosinophils109/l 29 0?400 (0?352)
Note:PC20 histaminewas signi¢cantlyhigher (*Po0?01) intheb
bdgroup andthetheophylline 300mgbdgroup.IgEwas signi¢cant
two budesonide groups.Statistical di¡erences between groupswewine, and during exercise.The severity of each symptom
was graded according to a score from 0^3 (0=none,
3= severe). Patients returned all unusedmedicine.
Compliance
Compliance was determined by weight, inhalers, and
tablet counts.
Statistics
A list for randomization to treatment was made by a
computer program.
Results were expressed as mean values7 SD and last
observed value has been extended in the periods 0^9
months and 9^12 months (intention-to-treat-analyses).
PC20 histamine was determined as geometric mean and
range. Calculations on PC20 were performed with the
base-2 logarithm (log2). E⁄cacy was evaluated by the
di¡erences from pretreatment (0^9 months) and
post-treatment (9^12 months).
Di¡erences within and between treatment groups
were analysed with t-tests and Mann^Whitney U test
for unpaired samples. Withdrawal rates were analyzed
by chi-squared test. P-values equal to or less than 0?05
were considered statistically signi¢cant.
RESULTS
Eighty-¢ve patients were enrolled in the study. Patient
characteristics at inclusion are shown inTable 1. Patient
characteristics at randomization were comparable
except that the budesonide 200mg bd group was lessSD
Budesonide 200 mg bd Theophylline SR 300mgbd
Number Mean (SD) Number Mean (SD)
29 27
10/19 14/13
29 46?7 (12?7) 27 45?1 (13?7)
29 6?8 (10?2) 27 13?5 (15?2)
29 68?2 (19?8) 27 68?0 (17?6)
27 12?4 (6?4) 24 15?7 (7?5)
27 0?71 (0?04^3?76)* 23 0?39 (0?04^3?73)
29 1?0 (0?5) 27 1?0 (0?5)
14/15 14/13
2/8 6/8
27 79 (163) 27 216 (273)**
27 0?371 (0?321) 26 0?382 (0?403)
udesonide 200 mgbdgroup comparedtothebudesonide 800 mg
lyhigher (**Po0?01) inthe theophylline group comparedtothe
re evaluated by Mann^Whitney U-test for unpaired samples.
FIG. 1. Percentage of patients in each group remaining in the
study during the 9-month treatment period and 3-month fol-
low-upperiod.Signi¢cantlymorepatientswithdrewinthetheo-
phylline group (Po0?01) during the treatmentperiod compared
to the two budesonide groups. No signi¢cant di¡erence be-
tween groups was found in the end of the 3-month follow-up
period.Budesonide 800 mg bd:F; budesonide 200 mg bd:y. ;
theophylline 300mgbd:- - - -.
FIG. 2. Percentage change in FEV1 from pretreatment value
(0^9 months) and from the value at 9 months (9^12 months) in
patientsinthe study (at 9months).Meanvalues7 SD.Budesonide
800 mgbd:F; budesonide 200 mgbd:y. ; theophylline 300mg
bd:- - - - -.
FIG. 3. The di¡erences in PC20 histamine, doubling dilutions
from pretreatment value (0^9 months) and from the value at 9
months forpatientsremaininginthe study (9^12months).Values
are expressedasgeometricmeanandrange.Budesonide 800 mg
bd:F; budesonide 200 mg bd:y. ; theophylline 300mg bd:
- - - - -.
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nide 800mg bd and the theophylline group (Po0?01), and
that the theophylline group had a higher IgE level com-
pared to the two budesonide groups (Po0?01).
Withdrawals
Thewithdrawal rate due to lackof e⁄cacyof studymed-
ication during the 9-month treatmentperiodwas signi¢-
cantly higher (Po0?01) in the theophylline group
compared to the twobudesonide groups. In the 3-month
follow-up period after termination of study treatment,
more patients withdrew in the two budesonide groups.
There was no signi¢cant di¡erence between withdrawal
rate in the budesonide groups. The percentage of pa-
tients remaining in the study during the 9-month treat-
ment period and the 3-month follow-up period are
shown in Fig.1.The actual number of patients in the three
treatment groups that completed the study and with-
drew during the study period at 9 and 12 months are
shown in Table 2. The reason for withdrawal in these
cases was asthma deterioration.TABLE 2. Numberof patients completed andwithdrawnduring t
At start 0^9 mont
Completed W
Budesonide 800 mg bd 29 23
Budesonide 200 mg bd 29 20
Theophylline SR 300mgbd 27 11
Note:Signi¢cantly (*Po0?01) more patientswithdrew in the the
were evaluated bychi-square test.Lung function
FEV1in percent of predictednormal valuewas not signif-
icantly di¡erent at randomization in the three treatment
groups.he studyperiod at 9 and12 months
hs At 9 months 9^12 months
ithdrawn Completed Withdrawn
6 23 10 13
9 20 7 13
16* 11 7 4
ophylline treated group. Statistical di¡erences between groups
FIG. 4. The di¡erences in asthma symptom score from pre-
treatment value (0^9 months) and from the value at 9 months
for patients remaining in the study (9^12 months). Mean value
7SD. Di¡erences during treatment and post treatment were
analyzed by paired t-test. Budesonide 800 mg bd:F; budeso-
nide 200 mgbd:y. ; theophylline 300mgbd:- - - - -
TABLE 3. Compliance in percent with dosage regime in the
budesonide groups and the theophylline group
Compliance
aerosols
Compliance
tablets
Budesonide 800 mg bd 88?1719?3 90?9711?8
Budesonide 200 mgbd 76?7725?1 83?9722?3
Theophylline 300mgbd 78?4753?3 87?6750?4
436 RESPIRATORYMEDICINEFEV1 percent predicted in the budesonide 800mg bd
group improved signi¢cantly after 1month compared to
baseline (Po0?01), (Fig. 2). The improvement persisted
through the 9-month treatment period. In the budeso-
nide 200mg bd group, FEV1 percent predicted increased
slightly.The increase was only signi¢cant (P=0?05) after
5 months of treatment. FEV1 percent predicted in the
theophylline group was unchanged during the 9-month
treatment period (Fig. 2).
After termination of study medication, FEV1 in the
800mg bd and 200mg bd budesonide groups fell signi¢-
cantly (Po0?01 and Po0?02, respectively) during the
¢rstmonth and reached pretreatment values.The theo-
phylline group had a slight but insigni¢cant deterioration
in FEV1after treatment termination (Fig. 2).FVC,VC, and
PEF in percent of predicted normal values were un-
changed during the study period in the three treatment
groups.
Bronchial reactivity
In the budesonide 800mg bd group, PC20 histamine de-
creased signi¢cantly after 1month’s treatment (Po0?01)and gradually decreased further, equivalent to two dou-
bling dilutions after 9 months of treatment (Po0?0001)
(Fig. 3). In the budesonide 200mg bd group, bronchial
reactivity decreased signi¢cantly (Po0?005) after 2
months of treatment and thereafter remained constant
during the treatment period. No change in bronchial
reactivity was evident during treatment with theophyl-
line. After termination of study medication, bronchial
reactivity increased signi¢cantly during the ¢rst month
in both the budesonide 800mg bd and 200mg bd groups
(Po0?002 and P=0?05, respectively) (Fig. 3).No change
inbronchialreactivityoccurredin the theophyllinegroup
after treatmentwas stopped.
Asthma symptomscore
Asthma severity was evaluated by asthma symptom
scores by questions asked at the clinic. At baseline
asthma symptom scores were low in the three treat-
mentgroups.Therewas a dose-related andhighly signi¢-
cant decrease in symptom scores after budesonide
800mg bd and budesonide 200mg bd treatment
(Po0?00001, and Po0?0001, respectively) (Fig. 4). After
theophylline treatment, symptom scores decreased
slightly and only signi¢cantly after 1 and 2 months of
treatment (Po0?01 and Po0?02, respectively). During
the rest of the theophylline treatment period the de-
crease in symptom scores was variable (0?07o
Po0?001).
After studymedicationwas stopped, no signi¢cant in-
crease in symptom scores was found in any of the three
treatment groups.
Compliance and adverse events
Compliance with both aerosols and tablets were high
and not di¡erent between treatment groups (Table 3).
Occasional and transient adverse events, such as hoarse-
ness, were seen.
DISCUSSION
This study showed that long-term treatment with
inhaled budesonide 800mg bd and 200mg bd was more
e¡ective than maintenance treatment with theophylline
300mg bd in asthmatic patients with mild to moderate
disease. Inhaled glucocorticosteroids caused a signi¢cant
increase in lung function, reduced bronchial reactivity
and reduced asthma symptoms. Theophylline reduced
asthma symptoms but did not alter bronchial reactivity
and lung function.
It was con¢rmed that a dose-related e¡ect exist for
topical glucocorticosteroid treatment (20) not only in
the short term but also during 9 months of treatment.
In the high-dose budesonide group, lung function, bron-
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the ¢rst month and to a higher degree compared to the
low-dose budesonide.This reduction in asthma severity
during glucocorticosteroid treatment is in accordance
with previous studies (13,14). Bronchial reactivity is asso-
ciatedwith in£ammation (21) and, in accordancewith the
anti-in£ammatory e¡ect of topical glucocorticosteroids
(22), we found a dose-related e¡ect of budesonide on
PC20 histamine.Theophylline did not alter bronchial re-
activity and probably has minor in£uence on in£amma-
tory factors that in£uence bronchial reactivity.
The improvement in lung function in the glucocorti-
costeroid groups occurred within the ¢rst month of
treatment and was maintained at that level during the
treatment period. Bronchial reactivity decreased gradu-
ally and continuously in the high-dose budesonide group
during the 9-month treatment period.This con¢rms the
£at dose^response for corticosteroids with respect to
lung function and a more steep response and discrimina-
tion in bronchial reactivity measures (23,24). The disso-
ciation between lung function and bronchial reactivity
gives rise to the thoughts that patients may be better
monitored by including measures of reactivity in the as-
sessment because increased reactivity is a risk factor for
asthma exacerbations. However, FEV1 and PC20 did not
become normal and inmany patients a degree of irrever-
sible damage may have been present because of long-
standing asthma. Genetics and at present unknown
factors may, however, play a role in determining airways
reactivity, even after several years of inhaled glucocorti-
costeroid bronchial biopsies contained no in£ammatory
changes although bronchial reactivity was still present
(25).The fast deterioration in FEV1andbronchial reactiv-
ity after glucocorticosteroid treatment was stopped
may re£ect recurrence of in£ammation in the airway
mucosa.These results indicate that glucocorticosteroids
treatment is a symptomatic treatment that should be
taken as regular maintenance treatment to reduce
asthma manifestations. Few patients in the theophylline
group deteriorated after treatment was stopped
probably because most patients in that group had dete-
riorated and already left the study and the remaining
patients couldmanagewithout the drug.
Asthma severity has been related to the degree of
bronchial reactivity (19) but we were unable to demon-
strate any correlation between asthma symptom score,
bronchial reactivity and lung function.The number of pa-
tients in this studymay havebeen too few to detect such
correlations, but if these relations were important and
strong this should have been evident.
The withdrawal rates due to asthma deterioration
were low during the ¢rst 2 months in all treatment
groups. In the glucocorticosteroid groups the withdra-
wals continued at low rates during the treatment period
with fewest drop-outs in the high-dose budesonide
group. Among the patients only treated with theophyl-line, a substantial number were withdrawn due to ex-
acerbations of asthma. After discontinuation of study
medication the withdrawal rates were higher among
the glucocorticosteroid treated patients and the dete-
rioration occurred within the ¢rst month, indicating
the need for continuous inhaled corticosteroid.
This study allowedus to evaluate the long-terme¡ects
of glucocorticosteroid treatment, the dose^response
e¡ects and the evolution in the asthma manifestation
after discontinuation of steroids. Also, we were able to
compare steroid treatment with theophylline therapy.
The results of this study showed that long-term treat-
ment with a high dose of inhaled budesonide was super-
ior to a low daily budesonide dose and oral theophylline
in improvementof lung function, bronchial reactivity and
asthma symptoms.Glucocorticosteroid therapyreduced
bronchialreactivity,whichmayre£ect airways in£amma-
tion that is considered to be one of the pathophysiologi-
cally important mechanisms in asthma. It seems the
duration of treatment shouldbe at least 6months before
themaximumbene¢t and protection has been achieved.
When choosing among the parameters to monitor the
e¡ects of asthma treatment, the fastest response was
found in asthma symptoms which may be the most
sensitive response parameter. Then lung function im-
proved more slowly over weeks and the most resistant
parameter was airways histamine reactivity. We were
not able to study the reason for this time and e¡ect
in£uence on treatment outcome, or which of the
response parameters that was of most clinical impor-
tance for long-term outcome in preserving lung function
and inhibition of asthma deterioration.
The results strongly suggest that theophylline should
not be used as monotherapy and support the idea that
inhaledglucocorticosteroids at present are themost im-
portant and reliable symptomatic treatments available.
Recommendations as to the optimum dose of gluco-
corticosteroids are, therefore, di⁄cult to give. If it is of
great importance to reduce bronchial reactivity asmuch
as possible, patients should be persuaded to use higher
dosages than those that improve lung function and
reduce symptoms and treatment should last for at least
9 months. Before such recommendation can be given,
more information is needed.The time for recurrence of
asthma manifestations after stopping the inhaled
glucocorticosteroid implies that when attempts are
made to reduce glucocorticosteroids this shouldbe done
gradually andwith intervals not less than 4 weeks.
Acknowledgements
Astra Draco, Lund, Sweden, supplied the study medica-
tion and supported the study. Roberta Karlstr˛m is
thanked for her skilful monitoring and Torr Persson for
performing the statistical analysis.
438 RESPIRATORYMEDICINEREFERENCES
1. Glynn AA, Michaels L. Bronchial biopsy in chronic bronchitis and
asthma.Thorax1960; 15: 42^53.
2. Laitinen LA,HeinoM,LaitinenA,KavaT,HaahtelaT.Damage of the
airway epithelium andbronchial reactivity in patients with asthma.
Am Rev Respir Dis1985; 131: 599^606.
3. Peat JK,Woolcock AJ,Cullen K. Rate of decline of lung function in
subjects with asthma.Eur J Respir Dis1987; 70:171^179.
4. Gerritsen J,Koeter GH,Postma DS, Schouten JP,Knol K. Prognosis
of asthma from childhood to adulthood. Am Rev Respir Dis 1989;
140:1325^1330,
5. Fuglsang G, Hertz B, Holm EB. No protection by oral terbutaline
against exercise-induced asthma in children: a dose-response study.
Eur Respir J1993; 6: 527^530.
6. Sze£er SJ, Nelson HS. Alternative agents for anti-in£ammatory
treatment of asthma.J Allergy Clin Immunol1998; 102: S23^S35.
7. Lim S, Tomita K, Carramori G, Jatakanon A, Oliver B, Keller A,
Adcock I, Chung KF, Barnes PJ. Low-dose theophylline reduces
eosinophilic in£ammationbut not exhaled nitric oxide inmild asth-
ma. Am J Respir Crit CareMed 2001; 164: 273^276.
8. Barnes PJ. A new approach to the treatment of asthma. N Engl J
Med1989; 321:1517^1527.
9. Kraan J,KoeterGH, vdMarkTW, Sluiter HJ,DeVries K.Changes in
bronchial hyperreactivity induced by 4 weeks of treatment with
antiasthmatic drugs in patients with allergic asthma: a comparison
betweenbudesonide and terbutaline.J AllergyClin Immunol1985; 76:
628^636.
10. Waalkens HJ, Gerritsen J, Koeter GH, Krouwels FH, van Aalderen
WM, Knol K. Budesonide and terbutaline or terbutaline alone in
children with mild asthma: e¡ects on bronchial hyperresponsive-
ness and diurnal variation in peak £ow.Thorax1991; 46: 499^503.
11. Kerrebijn KF, Essen-Zandvliet EE, Neijens HJ. E¡ect of long-term
treatment with inhaled corticosteroids and beta-agonists on the
bronchial responsiveness in children with asthma. J Allergy Clin
Immunol1987; 79: 653^659.
12. Juniper EF, Kline PA,VanzieleghemMA,Ramsdale EH,O’Byrne PM,
Hargreave FE. E¡ect of long-term treatmentwith an inhaled corti-
costeroid (budesonide) on airway hyperresponsiveness and clinical
asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis
1990; 142: 832^836.
13. HaahtelaT, JarvinenM,KavaT,Kiviranta K,Koskinen S, Lehtonen K,
Nikander K, PerssonT, Reinikainen K, Selroos O.Comparison of a
beta-2 agonist, terbutaline, with an inhaled corticosteroid, bude-
sonide, in newly detected asthma.NEngl JMed1991; 325: 388^392..14. KerstjensHA, Brand PL,HughesMD,RobinsonNJ,PostmaDS, Slui-
ter HJ, Bleecker ER, Dekhuijzen PN, de Jong PM, Mengelers HJ. A
comparison of bronchodilator therapy with or without inhaled
corticosteroid therapy for obstructive airways disease. Dutch
Chronic Non-Speci¢c Lung Disease Study Group. N Engl J Med
1992; 327:1413^1419.
15. Pedersen B,Dahl R,Karlstrom R, Peterson CG,Venge P. Eosinophil
and neutrophil activity in asthma in a one-year trial with inhaled
budesonide. The impact of smoking. Am J Respir Crit Care Med
1996; 153:1519^1529.
16. American Thoracic Society Commitee on Diagnostic Standards.
De¢nitions and classi¢cation of chronic bronchitis, asthma, and
pulmonary empaysema. Am Rev Respir Dis1962; 85: 762.
17. Quanjer PHed. Report Working Party Standardization of Lung
FunctionTests, European Community for Steel and Coal. O⁄cial
Statement of the European Respiratory Society. Eur Respir J 1993;
16(Suppl):1^95.
18. International Consensus Report on Diagnosis and Treatment of
Asthma.Clin Exp Allergy1992; 22(Supp) 1:1^72.
19. Cockcroft DW,Killian DN,Mellon JJ, Hargreave FE. Bronchial reac-
tivity to inhaled histamine: a method and clinical survey.Clin Allergy
1997; 7: 235^243.
20. Toogood JH.High-dose inhaled steroid therapy for asthma.J Allergy
Clin Immunol1989; 83: 528^536.
21. Wardlaw AJ, Dunnette S,Gleich GJ, Collins JV, Kay AB. Eosinophils
andmast cells in bronchoalveolar lavage in subjectswithmild asth-
ma. Relationship to bronchial hyperreactivity. Am Rev Respir Dis
1988; 137: 62^69.
22. Adelroth E, Rosenhall L, Johansson SA, Linden M,Venge P. In£am-
matory cells and eosinophilic activity in asthmatics investigated by
bronchoalveolar lavage. The e¡ects of antiasthmatic treatment
with budesonide or terbutaline. Am Rev Respir Dis 1990; 142:
91^99.
23. Pedersen S, Hansen OR. Budesonide treatment of moderate and
severe asthma in children: a dose-response study. J Allergy Clin I
mmunol1995; 95: 29^33.
24. Wilson AM, Lipworth BJ. Dose-response evaluation of the thera-
peutic index for inhaled budesonide in patients with mild-to-mod-
erate asthma. Am JMed 2000; 108: 269^275.
25. Lundgren R, Soderberg M, Horstedt P, Stenling R. Morphological
studies of bronchial mucosal biopsies from asthmatics before and
after ten years of treatment with inhaled steroids. Eur Respir J
1988; 1: 883^889.
